Literature DB >> 11239944

Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs.

H Reiber1, J B Peter.   

Abstract

Cerebrospinal fluid (CSF) analysis is a basic tool for diagnosis of neurological diseases. Knowledge regarding blood-CSF barrier function (molecular flux/CSF flow theory) and neuroimmunology is reviewed to aid understanding and evaluation of CSF data. Disease-related immunoglobulin patterns (IgG, IgA, IgM with reference to albumin) are described in CSF/serum quotient diagrams with the hyperbolic reference range for blood-derived protein fractions in CSF. Clinical relevance of complementary analyses (cytology, PCR, oligoclonal IgG, antibody detection and brain-derived proteins) is briefly discussed. Integrated CSF data reports are shown with numerical and graphical data representation, reference range-related interpretation and diagnosis-related comments. The principles and rationale of general CSF analysis reported in this review should enable the reader to accurately interpret CSF data profiles, and to plan a proper evaluation of new brain- or blood-derived analytes in CSF.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11239944     DOI: 10.1016/s0022-510x(00)00501-3

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  189 in total

1.  CSF abnormalities can be predicted by VEP and MRI pathology in the examination of optic neuritis.

Authors:  Henrik Horwitz; Matilda Degn; Signe Modvig; Henrik B W Larsson; Benedikte Wanscher; Jette L Frederiksen
Journal:  J Neurol       Date:  2012-06-06       Impact factor: 4.849

2.  Childhood multiple sclerosis and related disorders.

Authors:  Amna Al-Futaisi
Journal:  Oman Med J       Date:  2007-10

3.  Cerebrospinal fluid under non-steady state condition caused by plasmapheresis.

Authors:  Dominik Madžar; Christian Maihöfner; Rüdiger Zimmermann; Stefan Schwab; Johannes Kornhuber; Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2010-11-16       Impact factor: 3.575

4.  Rostrocaudal dynamics of CSF biomarkers.

Authors:  Andrew Tarnaris; Ahmed K Toma; Miles D Chapman; Axel Petzold; Geoff Keir; Neil D Kitchen; Laurence D Watkins
Journal:  Neurochem Res       Date:  2010-12-30       Impact factor: 3.996

5.  Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity.

Authors:  C Hammer; B Stepniak; A Schneider; S Papiol; M Tantra; M Begemann; A-L Sirén; L A Pardo; S Sperling; S Mohd Jofrry; A Gurvich; N Jensen; K Ostmeier; F Lühder; C Probst; H Martens; M Gillis; G Saher; F Assogna; G Spalletta; W Stöcker; T F Schulz; K-A Nave; H Ehrenreich
Journal:  Mol Psychiatry       Date:  2013-09-03       Impact factor: 15.992

6.  The chaperone protein clusterin may serve as a cerebrospinal fluid biomarker for chronic spinal cord disorders in the dog.

Authors:  Intan N F Shafie; Mark McLaughlin; Richard Burchmore; Mary Ann A Lim; Paul Montague; Pamela E J Johnston; Jacques Penderis; Thomas J Anderson
Journal:  Cell Stress Chaperones       Date:  2013-08-29       Impact factor: 3.667

Review 7.  Anti-cyclic citrullinated peptide antibody in the cerebrospinal fluid in patients with rheumatoid arthritis who have central nervous system involvement.

Authors:  Misako Higashida-Konishi; Keisuke Izumi; Masako Tsukamoto; Hiroaki Ohya; Nozomi Takasugi; Satoshi Hama; Yutaro Hayashi; Mari Ushikubo; Kumiko Akiya; Araki Kazuhiro; Yutaka Okano; Hisaji Oshima
Journal:  Clin Rheumatol       Date:  2020-04-30       Impact factor: 2.980

8.  Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases.

Authors:  Sarah Jesse; Johannes Brettschneider; Sigurd D Süssmuth; Bernhard G Landwehrmeyer; Christine A F von Arnim; Albert C Ludolph; Hayrettin Tumani; Markus Otto
Journal:  J Neurol       Date:  2010-12-25       Impact factor: 4.849

Review 9.  Biomarkers: potential uses and limitations.

Authors:  Richard Mayeux
Journal:  NeuroRx       Date:  2004-04

10.  Comparison of Clinical Course and Treatment Outcome for Patients With Early Disseminated or Early Localized Lyme Borreliosis.

Authors:  Daša Stupica; Vera Maraspin; Petra Bogovic; Katarina Ogrinc; Rok Blagus; Tjaša Cerar; Franc Strle
Journal:  JAMA Dermatol       Date:  2018-09-01       Impact factor: 10.282

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.